Sa1113 Is Intravenous Immunoglobulin (IVIG) Therapy Beneficial in Reducing Utilizations of Healthcare Resources in Patients With Drug and Device Refractory Symptoms of Gastroparesis?

Munish Ashat; Amanda Lewis; Hammad Liaquat; Chirag M. Patel; Abigail Stocker; Lindsay McElmurray; Teresa Cutts; Thomas L. Abell

doi:10.1016/S0016-5085(16)30886-1

$Sa1113 Is Intravenous Immunoglobulin (IVIG) Therapy Beneficial in Reducing Utilizations of Healthcare Resources in Patients With Drug and Device Refractory Symptoms of Gastroparesis?$

Abstract

Peer reviewed

Sa1113 Is Intravenous Immunoglobulin (IVIG) Therapy Beneficial in Reducing Utilizations of Healthcare Resources in Patients With Drug and Device Refractory Symptoms of Gastroparesis?

Munish Ashat, Amanda Lewis, Hammad Liaquat, Chirag M. Patel, Abigail Stocker, Lindsay McElmurray, Teresa Cutts and Thomas L. Abell

Gastroenterology (New York, N.Y. 1943), Vol.150(4), pp.S244-S245

04/2016

DOI: 10.1016/S0016-5085(16)30886-1

View Online

Details

Title: Subtitle: Sa1113 Is Intravenous Immunoglobulin (IVIG) Therapy Beneficial in Reducing Utilizations of Healthcare Resources in Patients With Drug and Device Refractory Symptoms of Gastroparesis?
Creators: Munish Ashat
Amanda Lewis
Hammad Liaquat
Chirag M. Patel
Abigail Stocker
Lindsay McElmurray
Teresa Cutts
Thomas L. Abell
Resource Type: Abstract
Publication Details: Gastroenterology (New York, N.Y. 1943), Vol.150(4), pp.S244-S245
DOI: 10.1016/S0016-5085(16)30886-1
ISSN: 0016-5085
eISSN: 1528-0012
Language: English
Date published: 04/2016
Academic Unit: Internal Medicine
Record Identifier: 9984361571402771

Metrics

12 Record Views